Potential therapeutic targets in the NF-κB pathway for Alzheimer's disease

Drug News and Perspectives

Volumn 18, Issue 10, 2005, Pages 623-629

  Collister, Kathryn A ^a   Albensi, Benedict C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BMS 345541; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PS 1145; SPC 839; THALIDOMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; DRUG MECHANISM; DRUG TARGETING; GENE ACTIVATION; HUMAN; MEMORY DISORDER; NONHUMAN; PATHOLOGY; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION INITIATION;

ALZHEIMER DISEASE; CREB-BINDING PROTEIN; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; HUMANS; MEMORY; NF-KAPPA B; TRANSCRIPTION FACTORS;

EID: 33645046630     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2005.18.10.959576     Document Type: Review

References (49)

1. The American Heritage® Stedman's Medical Dictionary. Houghton Mifflin Company, 2002.
2. Hebb, D.O. Chapter 4 - The first stage of perception: growth and assembly. In: The Organization of Behavior. Wiley: New York 1949.
3. Vitolo, O.V., Sant'Angelo, A., Costanzo, V., Battaglia, F., Arancio, O. and Shelanski, M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002, 99: 13217-21.
4. Masliah, E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995, 10: 509-19.
5. Albert, M.S. Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci U S A 1996, 93: 13547-51.
6. Goldman-Rakic, P.S. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A 1996, 93: 13473-80.
7. Mukaetova-Ladinska, E.B., Garcia-Siera, F., Hurt, J. et al. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 2000, 157: 623-36.
8. Yeh, S.H., Lin, C.H. and Gean, P.W. Acetylation of nuclear factor-κB in rat amygdala improves long-term but not short-term retention of fear memory. Mol Pharmacol 2004, 65: 1286-92.
9. Albensi, B.C. and Mattson, M.P. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 2000, 35: 151-9.
10. Johannessen, M., Delghandi, M.P. and Moens, U. What turns CREB on? Cell Signal 2004, 16: 1211-27.
11. Lynch, G. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 2002, 5: 1035-8.
12. Hampson, R.E., Rogers, G., Lynch, G. and Deadwyler, S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 1998, 18: 2748-63.
13. Staubli, U., Rogers, G. and Lynch, G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci U S A 1994, 91: 777-81.
14. Jackson, T. and Ramaswami, M. Prospects of memory-modifying drugs that target the CREB pathway. Curr Opin Drug Discov Dev 2003, 6: 712-9.
15. Fang, J.Y. and Richardson, B.C. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005, 6: 322-7.
16. Echeverria, V., Ducatenzeiler, A., Dowd, E. et al. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience 2004, 129: 583-92.
17. Barad, M., Bourtchouladze, R., Winder, D.G., Golan, H. and Kandel, E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A 1998, 95: 15020-5.
18. Mattson, M.P. and Camandola, S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001, 107: 247-54.
19. Chen, L.F. and Greene, W.C. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004, 5: 392-401.
20. Barger, S.W., Moerman, A.M. and Mao, X. Molecular mechanisms of cytokine-induced neuroprotection: NFkappaB and neuroplasticity. Curr Pharm Des 2005, 11: 985-98.
21. Karin, M., Yamamoto, Y. and Wang, Q.M. The IKK NF-kappaB system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3: 17-26.
22. Yamamoto, Y., Verma, U.N., Prajapati, S., Kwak, Y.T. and Gaynor, R.B. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003, 423: 655-9.
23. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H. and Stark, G.R. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002, 277: 3863-9.
24. Hayden, M.S. and Ghosh, S. Signaling to NF-kappaB. Genes Dev 2004, 18: 2195-224.
25. Lilienbaum, A. and Israel, A. From calcium to NF-kappa B signaling pathways in neurons. Mol Cell Biol 2003, 23: 2680-98.
26. Meffert, M.K., Chang, J.M., Wiltgen, B.J., Fanselow, M.S. and Baltimore, D. NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci 2003, 6: 1072-8.
27. Mattson, M.P., Culmsee, C., Yu, Z. and Camandola, S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 2000, 74: 443-56.
28. Meffert, M.K. and Baltimore, D. Physiological functions for brain NF-kappaB. Trends Neurosci 2005, 28: 37-43.
29. Mattson, M.P. Free radicals, calcium, and the synaptic plasticity-cell death continuum: emerging roles of the transcription factor NF kappa B. Int Rev Neurobiol 1998, 42: 103-68.
30. Furukawa, K. and Mattson, M.P. The transcription factor NF-kappaB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by tumor necrosis factor-alpha in hippocampal neurons. J Neurochem 1998, 70: 1876-86.
31. Beraud, C., Henzel, W.J. and Baeuerle, P.A. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci U S A 1999, 96: 429-34.
32. Delhase, M., Li, N. and Karin, M. Kinase regulation in inflammatory response. Nature 2000, 406: 367-8.
33. Kane, L.P., Shapiro, V.S., Stokoe, D. and Weiss, A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999, 9: 601-4.
34. Ozes, O.N., Mayo, L.D., Gustin, J.A., Pfeffer, S.R., Pfeffer, L.M. and Donner, D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401: 82-5.
35. Romashkova, J.A. and Makarov, S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401: 86-90.
36. Mattson, M.P., Barger, S.W., Cheng, B., Lieberburg, I., Smith-Swintosky, V.L. and Rydel, R.E. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. Trends Neurosci 1993, 16: 409-14.
37. Marini, A.M., Jiang, X., Wu, X. et al. Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: From genes to phenotype. Restor Neurol Neurosci 2004, 22: 121-30.
38. Marini, A.M., Rabin, S.J., Lipsky, R.H. and Mocchetti, I. Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-D-aspartate. J Biol Chem 1998, 273: 29394-9.
39. Lipsky, R.H., Xu, K., Zhu, D. et al. Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J Neurochem 2001, 78: 254-64.
40. Bliss, T.V. and Collingridge, GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361: 31-9.
41. Bear, M.F. and Malenka, R.C. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol 1994, 4: 389-99.
42. Coussens, C.M. and Teyler, T.J. Protein kinase and phosphatase activity regulate the form of synaptic plasticity expressed. Synapse 1996, 24: 97-103.
43. Freudenthal, R., Boccia, M.M., Acosta, G.B. et al. NF-kappaB transcription factor is required for inhibitory avoidance long-term memory in mice. Eur J Neurosci 2005, 21: 2845-52.
44. Freudenthal, R. and Romano, A. Participation of Rel/NF-kappaB transcription factors in long-term memory in the crab Chasmagnathus. Brain Res 2000, 855: 274-81.
45. Freudenthal, R., Romano, A. and Routtenberg, A. Transcription factor NF-kappaB activation after in vivo perforant path LTP in mouse hippocampus. Hippocampus 2004, 14: 677-83.
46. Barger, S.W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J. and Mattson, M.P. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995, 92: 9328-32.
47. Bales, K.R., Du, Y., Dodel, R.C., Yan, G.M., Hamilton-Byrd, E. and Paul, S.M. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 1998, 57: 63-72.
48. Yin, M.J., Yamamoto, Y. and Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396: 77-80.
49. Keifer, J.A., Guttridge, D.C., Ashburner, B.P. and Baldwin, A.S., Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 2001, 276: 22382-7.